4-{4-[1-(2-dimethylamino-ethyl)-4-(4-fluoro-3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5,5-dimethyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one | 1226800-96-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-{4-[1-(2-dimethylamino-ethyl)-4-(4-fluoro-3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-piperidin-1-yl}-5,5-dimethyl-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one
• 英文别名: 4-[4-[1-[2-(dimethylamino)ethyl]-4-[4-fluoro-3-(trifluoromethyl)phenyl]imidazol-2-yl]piperidin-1-yl]-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one
• CAS: 1226800-96-9
• 化学式: C₂₇H₃₁F₄N₇O
• 分子量: 545.583
• InChiKey: FUNZWZGVCFAHRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• AKT AND P70 S6 KINASE INHIBITORS
  申请人：Shepherd Timothy Alan

  公开号：US20100120801A1

  公开（公告）日：2010-05-13

  The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of using compounds of Formula I.

  本发明提供了式子为AKT和p70 S6激酶抑制剂的药物。本发明还提供了包含式子I化合物的药物组合物，式子I化合物的用途以及使用式子I化合物的方法。
• NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US20190292190A1

  公开（公告）日：2019-09-26

  The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer. [In the formula, R 1 represents a 4- to 6-membered monocyclic unsaturated heterocyclic group which has 1 to 3 hetero atoms independently selected from N, S and O and may have a substituent; R 2 represents a hydrogen atom or the like; R 3 , R 4 , and R 5 , may be the same as or different from one another and independently represent a hydrogen atom or the like; R 6 represents a hydrogen atom or the like; R 7 and R 8 , may be the same as or different from each other and independently represent a hydrogen atom or the like; X 1 and X 2 may be the same as or different from each other and independently represent N or CR 9 ; R 9 represents a hydrogen atom or the like; and X 3 represents N or CH when the broken line ( ) represents a single bond, and represents C when a broken line indicates a double bond, wherein at least one of X 1 or X 2 represents N.]
• US8148387B2
  申请人：——

  公开号：US8148387B2

  公开（公告）日：2012-04-03
• [EN] AKT AND P70 S6 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE AKT ET P70 S6
  申请人：LILLY CO ELI

  公开号：WO2010056563A1

  公开（公告）日：2010-05-20

  The present invention provides AKT and p70 S6 kinase inhibitors of Formula (I). The present invention also provides pharmaceutical compositions comprising compounds of Formula (I), uses of compounds of Formula (I) and methods of using compounds of Formula (I).